

# CURE

Beyond  
**CIRM** 2.0  
CALIFORNIA'S STEM CELL AGENCY

*now it's personal*



**Gil Sambrano, Ph.D.**

Director of Portfolio Development and Review

# HOPE

# Funding Opportunities



**DISCOVERY**



**TRANSLATION**



**CLINICAL**

New Idea



Single Product Candidate



Pre-IND Meeting or Equivalent



Approved Therapy



1-2/Year



3/Year



12/Year

Program Offerings Per Year

# CIRM Translation Research Program (TRAN)



## Objective


To support promising stem cell-based projects that accelerate completion of translational stage activities necessary for advancement to clinical study or broad end use.

# What qualifies for TRAN?

Projects that propose a candidate:

- Therapeutic (TRAN 1)
- Diagnostic (TRAN 2)
- Medical device (TRAN 3)
- Tool (TRAN4)

# CIRM 2.0: Translation Program



# Review Criteria

- ✓ Does the project hold the necessary significance and potential for impact?
- ✓ Is the rationale sound?
- ✓ Is the project well planned and designed?
- ✓ Is the project feasible?

# Scoring System

- **Score of “85-100”**

*Recommended for funding, if funds are available*

- **Score of “1-84”**

*Not recommended for funding*

Applications are scored by all scientific members of the GWG with no conflict.

The **median** of all individual GWG scores determines final score.

# GWG Recommendations



	Number of Apps	Total Applicant Request	Funds Available
<b>Recommended for funding</b> Score 85-100	2	\$4,085,948	\$45,000,000
<b>Not recommended for funding</b> Score 1-84	9		

For each award, the final award amount shall not exceed the amount approved by the ICOC Application Review Subcommittee and may be reduced contingent on CIRM's assessment of allowable costs and activities.



# GWG Vote on Review Process

1. *All members*: “The review was scientifically rigorous, there was sufficient time for all viewpoints to be heard, and the scores reflect the recommendation of the GWG.”
2. *ICOC patient advocate members*: “The review was carried out in a fair manner and was free from undue bias.”

All members voted unanimously in favor of 1 (20-0)

Patient Advocate GWG members voted unanimously in favor of 2 (6-0)

# Overview of Recommended Applications

# TRAN4-09884

**TITLE:** A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific IPS Cells for Preclinical Drug Screening

**APPLICATION:** Testing drugs for possible cardiotoxicity

**PRODUCT TYPE:** Research tool – screening platform

# TRAN1-09814

**TITLE:** Injectable pro-regenerative scaffold for treating symptomatic peripheral artery disease

**INDICATION:** Peripheral artery disease

**PRODUCT TYPE:** Biologic